Literature DB >> 31577987

Sexual dysfunction in people with epilepsy.

Chaturbhuj Rathore1, Oliver J Henning2, Gerhard Luef3, Kurupath Radhakrishnan4.   

Abstract

Sexual dysfunction is a common comorbidity in people with epilepsy (PWE) that adversely affects their quality of life. Nearly one-half of men and women with epilepsy have sexual dysfunction, but in the majority, this often goes unnoticed. The wide variation in the reported prevalence of sexual dysfunction in PWE is due to the significant heterogeneity among the studies with regard to patient population, type and severity of epilepsy, number and type of antiseizure drugs (ASDs) used, and the tools used for assessing sexual dysfunction. Generally, patients with uncontrolled epilepsy, longer duration of epilepsy, focal epilepsy, higher seizure frequency, and those receiving enzyme-inducing and multiple ASDs are more likely to have sexual dysfunction. Women generally have dysfunction in the domains of desire, while males usually have arousal disorders such as erectile dysfunction and premature ejaculation. There is limited evidence to indicate that sexual function improves in patients rendered seizure-free following epilepsy surgery. Multiple mechanisms including direct effects of epilepsy, effects of ASDs, and psychosocial factors contribute to sexual dysfunction in epilepsy. Circumstantial evidence indicates that seizures and interictal epileptiform discharges can directly affect the hypothalamic-pituitary axis as well as production of gonadal steroids. Enzyme-inducing ASDs cause sexual dysfunction by affecting the metabolism of gonadal steroids. Limited data suggest that newer ASDs including oxcarbazepine, lamotrigine, and levetiracetam cause no or minimal sexual dysfunction. Depression and anxiety significantly contribute to sexual dysfunction in PWE. A multipronged and multidisciplinary approach is essential for optimizing the sexual functions. Every effort should be made to identify and treat reversible causes including changing to nonenzyme-inducing ASDs and to provide symptomatic relief. Large, prospective studies are required to improve our understanding on prevalence and mechanisms of sexual dysfunction in PWE.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antiseizure drugs; Epilepsy surgery; Erectile dysfunction; Hypersexuality; Hyposexuality

Year:  2019        PMID: 31577987     DOI: 10.1016/j.yebeh.2019.106495

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  6 in total

Review 1.  Sexual Dysfunction of Patients with Diffuse Low-Grade Glioma: A Qualitative Review of a Neglected Concern.

Authors:  Arnaud Lombard; Hugues Duffau
Journal:  Cancers (Basel)       Date:  2022-06-20       Impact factor: 6.575

2.  Spermatorrhea in a Chinese patient with temporal lobe epilepsy: a case report.

Authors:  Liang Zhang; Hao Yu; Dan Li; Hui Qian; Yuchao Chen
Journal:  J Int Med Res       Date:  2021-01       Impact factor: 1.671

3.  Sexual Dysfunction in Male Patients with Idiopathic Generalized Tonic Clonic Seizures.

Authors:  Rajendra Kumar Sureka; Vikas Gaur; Gaurav Purohit; Medha Gupta
Journal:  Ann Indian Acad Neurol       Date:  2021-08-04       Impact factor: 1.383

4.  Characteristics of menstrual disorders and reproductive hormones in women with epilepsy at an Indonesian national referral hospital.

Authors:  Fitri Octaviana; Kanadi Sumapraja; Winnugroho Wiratman; Luh Ari Indrawati; Astri Budikayanti
Journal:  Front Neurol       Date:  2022-09-20       Impact factor: 4.086

5.  Depression and sexual functions in epilepsy patients: Comparison before and during the COVID-19 pandemic.

Authors:  Zeynep Bastug Gul
Journal:  Ann Med Psychol (Paris)       Date:  2021-02-16       Impact factor: 0.380

6.  Influence of COVID-19 pandemic on sexuality: a cross-sectional study among couples in Turkey.

Authors:  Mehmet Ali Karagöz; Abdullah Gül; Charmaine Borg; İsmet Bilger Erihan; Mehmet Uslu; Mehmet Ezer; Ahmet Erbağcı; Binali Çatak; Murat Bağcıoğlu
Journal:  Int J Impot Res       Date:  2020-12-16       Impact factor: 2.408

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.